La inmunoterapia con atezolizumab duplica la supervivencia en cáncer de pulmón temprano. Análisis del ensayo IMpower030 presentado en la IASLC.

The diagnosis of lung adenocarcinoma in Pope Leo XIV highlights the need for advancements in treatment options for lung cancer, affecting millions globally.

Ivonescimab topped pembrolizumab alone or paired with chemotherapy in separate trials

Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...

Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...

Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...

Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...

Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...

Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding–based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer (WCLC).

Enhertu Becomes First HER2-Targeted Therapy to Beat Standard Care in Frontline Lung Cancer, Extending Time Without Progression by Six MonthsAstraZeneca and Daiichi Sankyo have announced positive resul...

Bispecific antibody and ADC together impress in early study

Enhertu Becomes First HER2-Targeted Therapy to Beat Standard Care in Frontline Lung Cancer, Extending Time Without Progression by Six MonthsAstraZeneca and Daiichi Sankyo have announced positive resul...

Enhertu Becomes First HER2-Targeted Therapy to Beat Standard Care in Frontline Lung Cancer, Extending Time Without Progression by Six MonthsAstraZeneca and Daiichi Sankyo have announced positive resul...

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Early efficacy among the highest seen in lung cancer, expert says

In the SWOG S1827 MAVERICK Phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure-free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, South Korea.

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).